Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: The emerging role of tetraspanins and rhomboids

Platelets

Volumn 28, Issue 4, 2017, Pages 333-341

  Matthews, Alexandra L ^a   Noy, Peter J ^a   Reyat, Jasmeet S ^a   Tomlinson, Michael G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

ADAM10; ADAM17; iRhom; platelet; tetraspanin; TspanC8

Indexed keywords

ADAM10 ENDOPEPTIDASE; MEMBRANE PROTEIN; PROTEASE INACTIVE RHOMBOID 1; PROTEASE INACTIVE RHOMBOID 2; SERINE PROTEINASE; TETRASPANIN; TETRASPANIN 10; TETRASPANIN 14; TETRASPANIN 15; TETRASPANIN 17; TETRASPANIN 33; TETRASPANIN 5; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; ADAM17 PROTEIN, HUMAN; DISINTEGRIN;

CELL SURFACE; ENDOPLASMIC RETICULUM; ENZYME REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEOMICS; REVIEW; ANIMAL; METABOLISM;

ADAM10 PROTEIN; ADAM17 PROTEIN; ANIMALS; DISINTEGRINS; HUMANS; TETRASPANINS;

EID: 85020874670     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537104.2016.1184751     Document Type: Review

References (103)

1. Khokha R, Murthy A, Weiss A., Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol 2013;13:649–665.
2. Klein T, Bischoff R., Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family:biological function and structure. J Proteome Res 2011;10:17–33.
3. Dreymueller D, Uhlig S, Ludwig A., ADAM-family metalloproteinases in lung inflammation:potential therapeutic targets. Am J Physiol Lung Cell Mol Physiol 2015;308:L325–43.
4. Saftig P, Reiss K., The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol 2011;90:527–35.
5. Bozkulak EC, Weinmaster G., Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol 2009;29:5679–5695.
6. Groot AJ, Habets R, Yahyanejad S, Hodin CM, Reiss K, Saftig P, Theys J, Vooijs M., Regulated proteolysis of NOTCH2 and NOTCH3 receptors by ADAM10 and presenilins. Mol Cell Biol 2014;34:2822–2832.
7. Rooke J, Pan D, Xu T, Rubin GM. KUZ, a conserved metalloprotease-disintegrin protein with two roles in Drosophila neurogenesis. Science 1996;273:1227–1231.
8. van Tetering G, van Diest P, Verlaan I, van der Wall E, Kopan R, Vooijs M., Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem 2009;284:31018–1027.
9. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 2004;113:1456–1464.
10. Altmeppen HC, Prox J, Krasemann S, Puig B, Kruszewski K, Dohler F, Bernreuther C, Hoxha A, Linsenmeier L, Sikorska B, et al. The sheddase ADAM10 is a potent modulator of prion disease. Elife 2015;4:e04260.
11. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel CP., Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004;164:769–779.
12. Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, de Strooper B, Hartmann D, Saftig P., ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci U S A 2005;102:9182–9187.
13. Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D, Saftig P., ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J 2005;24:742–52.
14. Schulz B, Pruessmeyer J, Maretzky T, Ludwig A, Blobel CP, Saftig P, Reiss K., ADAM10 Regulates Endothelial Permeability and T-Cell Transmigration by Proteolysis of Vascular Endothelial Cadherin. Circ Res 2008;102:1192–1201.
15. Anderegg U, Eichenberg T, Parthaune T, Haiduk C, Saalbach A, Milkova L, Ludwig A, Grosche J, Averbeck M, Gebhardt C, et al. ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. J Invest Dermatol 2009;129:1471–1482.
16. Hundhausen C, Schulte A, Schulz B, Andrzejewski MG, Schwarz N, von Hundelshausen P, Winter U, Paliga K, Reiss K, Saftig P, et al. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol 2007;178:8064–8072.
17. Weskamp G, Ford JW, Sturgill J, Martin S, Docherty AJ, Swendeman S, Broadway N, Hartmann D, Saftig P, Umland S, et al. ADAM10 is a principal ‘sheddase’ of the low-affinity immunoglobulin E receptor CD23. Nat Immunol 2006;7:1293–1298.
18. Donners MM, Wolfs IM, Olieslagers S, Mohammadi-Motahhari Z, Tchaikovski V, Heeneman S, van Buul JD, Caolo V, Molin DG, Post MJ, et al. A disintegrin and metalloprotease 10 is a novel mediator of vascular endothelial growth factor-induced endothelial cell function in angiogenesis and is associated with atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30:2188–2195.
19. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lubke T, Lena Illert A, von Figura K, et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 2002;11:2615–2624.
20. Maretzky T, Evers A, Le Gall S, Alabi RO, Speck N, Reiss K, Blobel CP., The cytoplasmic domain of a disintegrin and metalloproteinase 10 (ADAM10) regulates its constitutive activity but is dispensable for stimulated ADAM10-dependent shedding. J Biol Chem 2015;290:7416–7425.
21. Hartmann M, Parra LM, Ruschel A, Lindner C, Morrison H, Herrlich A, Herrlich P., Inside-out Regulation of Ectodomain Cleavage of Cluster-of-Differentiation-44 (CD44) and of Neuregulin-1 Requires Substrate Dimerization. J Biol Chem 2015;290:17041–17054.
22. Parra LM, Hartmann M, Schubach S, Li Y, Herrlich P, Herrlich A., Distinct Intracellular Domain Substrate Modifications Selectively Regulate Ectodomain Cleavage of NRG1 or CD44. Mol Cell Biol 2015;35:3381–3395.
23. Le Gall SM, Maretzky T, Issuree PD, Niu XD, Reiss K, Saftig P, Khokha R, Lundell D, Blobel CP., ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci 2010;123:3913–3922.
24. Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, Schirmacher P, Hartmann D, Cichy J, Gavrilova O, Schreiber S, et al. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med 2010;207:1617–1624.
25. Franzke CW, Cobzaru C, Triantafyllopoulou A, Loffek S, Horiuchi K, Threadgill DW, Kurz T, van Rooijen N, Bruckner-Tuderman L, Blobel CP., Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. J Exp Med 2012;209:1105–1119.
26. Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, Patterson C, Lee DC., Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. Embo j 2003;22:2704–2716.
27. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, Werb Z., Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development 2005;132:3923–3933.
28. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, et al. An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281–1284.
29. Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G, D’Souza SE. Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem 2006;281:3157–64.
30. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ, Black RA., Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 2000;275:14608–14614:ra34.
31. Xu PL, Liu JM, Sakaki-Yumoto M, Derynck R., TACE Activation by MAPK-Mediated Regulation of Cell Surface Dimerization and TIMP3 Association. Science Signaling 2012;5:ra34.
32. Deng W, Cho SY, Su PC, Berger BW, Li RH., Membrane-enabled dimerization of the intrinsically disordered cytoplasmic domain of ADAM10. Proceedings of the National Academy of Sciences of the United States of America 2014;111:15987–15992.
33. Dusterhoft S, Jung S, Hung CW, Tholey A, Sonnichsen FD, Grotzinger J, Lorenzen I., Membrane-Proximal Domain of a Disintegrin and Metalloprotease-17 Represents the Putative Molecular Switch of Its Shedding Activity Operated by Protein-disulfide Isomerase. J Am Chem Soc 2013;135:5776–5781.
34. Wang Y, Herrera AH, Li Y, Belani KK, Walcheck B., Regulation of Mature ADAM17 by Redox Agents for L-Selectin Shedding. J Immunol 2009;182:2449–2457.
35. Willems SH, Tape CJ, Stanley PL, Taylor NA, Mills IG, Neal DE, McCafferty J, Murphy G., Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem J 2010;428:439–450.
36. Lamour NF, Wijesinghe DS, Mietla JA, Ward KE, Stahelin RV, Chalfant CE., Ceramide kinase regulates the production of tumor necrosis factor alpha (TNF alpha) via inhibition of TNF alpha-converting enzyme. Journal of Biological Chemistry 2011;286:42808–42817.
37. Bender M, Hofmann S, Stegner D, Chalaris A, Bosl M, Braun A, Scheller J, Rose-John S, Nieswandt B., Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood 2010;116:3347–3355.
38. Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC., Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost 2007;5:1530–1537.
39. Alshehri OM, Hughes CE, Montague S, Watson SK, Frampton J, Bender M, Watson SP., Fibrin activates GPVI in human and mouse platelets. Blood 2015;126:1601–1608.
40. Mammadova-Bach E, Ollivier V, Loyau S, Schaff M, Dumont B, Favier R, Freyburger G, Latger-Cannard V, Nieswandt B, Gachet C, et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood 2015;126:683–691.
41. Bergmeier W, Piffath CL, Cheng G, Dole VS, Zhang Y, von Andrian UH, Wagner DD., Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res 2004;95:677–683.
42. Rabie T, Strehl A, Ludwig A, Nieswandt B., Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V. J Biol Chem 2005;280:14462–14468.
43. Bryckaert M, Rosa JP, Denis CV, Lenting PJ., Of von Willebrand factor and platelets. Cell Mol Life Sci 2015;72:307–326.
44. Metharom P, Berndt MC, Baker RI, Andrews RK., Current state and novel approaches of antiplatelet therapy. Arterioscler Thromb Vasc Biol 2015;35:1327–1338.
45. Inoshima I, Inoshima N, Wilke GA, Powers ME, Frank KM, Wang Y, Bubeck Wardenburg J., A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat Med 2011;17:1310–1314.
46. Powers ME, Becker RE, Sailer A, Turner JR, Bubeck Wardenburg J., Synergistic Action of Staphylococcus aureus alpha-Toxin on Platelets and Myeloid Lineage Cells Contributes to Lethal Sepsis. Cell Host Microbe 2015;17:775–787.
47. Gardiner EE, Andrews RK., Platelet receptor expression and shedding:glycoprotein Ib-IX-V and glycoprotein VI. Transfus Med Rev 2014;28:56–60.
48. Hofmann S, Vogtle T, Bender M, Rose-John S, Nieswandt B., The SLAM family member CD84 is regulated by ADAM10 and calpain in platelets. J Thromb Haemost 2012;10:2581–2592.
49. Mou P, Zeng Z, Li Q, Liu X, Xin X, Wannemacher KM, Ruan C, Li R, Brass LF, Zhu L., Identification of a calmodulin-binding domain in Sema4D that regulates its exodomain shedding in platelets. Blood 2013;121:4221–4230.
50. Zhu L, Bergmeier W, Wu J, Jiang H, Stalker TJ, Cieslak M, Fan R, Boumsell L, Kumanogoh A, Kikutani H, et al. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci U S A 2007;104:1621–1626.
51. Charrin S, Jouannet S, Boucheix C, Rubinstein E., Tetraspanins at a glance. J Cell Sci 2014;127:3641–3648.
52. Hemler ME., Tetraspanin proteins promote multiple cancer stages. Nat Rev Cancer 2014;14:49–60.
53. Min G, Wang H, Sun TT, Kong XP., Structural basis for tetraspanin functions as revealed by the cryo-EM structure of uroplakin complexes at 6-A resolution. J Cell Biol 2006;173:975–983.
54. Zuidscherwoude M, Gottfert F, Dunlock VM, Figdor CG, van den Bogaart G, van Spriel AB. The tetraspanin web revisited by super-resolution microscopy. Sci Rep 2015;5:12201.
55. Lammerding J, Kazarov AR, Huang H, Lee RT, Hemler ME., Tetraspanin CD151 regulates alpha6beta1 integrin adhesion strengthening. Proc Natl Acad Sci U S A 2003;100:7616–7621.
56. Winterwood NE, Varzavand A, Meland MN, Ashman LK, Stipp CS., A critical role for tetraspanin CD151 in alpha3beta1 and alpha6beta4 integrin-dependent tumor cell functions on laminin-5. Mol Biol Cell 2006;17:2707–2721.
57. Yang XH, Richardson AL, Torres-Arzayus MI, Zhou P, Sharma C, Kazarov AR, Andzelm MM, Strominger JL, Brown M, Hemler ME., CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. Cancer Res 2008;68:3204–3213.
58. Baldwin G, Novitskaya V, Sadej R, Pochec E, Litynska A, Hartmann C, Williams J, Ashman L, Eble JA, Berditchevski F., Tetraspanin CD151 regulates glycosylation of (alpha)3(beta)1 integrin. J Biol Chem 2008;283:35445–35454.
59. Yang XH, Mirchev R, Deng X, Yacono P, Yang HL, Golan DE, Hemler ME., CD151 restricts the alpha6 integrin diffusion mode. J Cell Sci 2012;125:1478–1487.
60. Levy S., Function of the tetraspanin molecule CD81 in B and T cells. Immunol Res 2014;58:179–185.
61. Junge HJ, Yang S, Burton JB, Paes K, Shu X, French DM, Costa M, Rice DS, Ye W., TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling. Cell 2009;139:299–311.
62. Barreiro O, Zamai M, Yanez-Mo M, Tejera E, Lopez-Romero P, Monk PN, Gratton E, Caiolfa VR, Sanchez-Madrid F., Endothelial adhesion receptors are recruited to adherent leukocytes by inclusion in preformed tetraspanin nanoplatforms. J Cell Biol 2008;183:527–542.
63. Doyle EL, Ridger V, Ferraro F, Turmaine M, Saftig P, Cutler DF., CD63 is an essential cofactor to leukocyte recruitment by endothelial P-selectin. Blood 2011;118:4265–4273.
64. Karamatic Crew V, Burton N, Kagan A, Green CA, Levene C, Flinter F, Brady RL, Daniels G, Anstee DJ., CD151, the first member of the tetraspanin (TM4) superfamily detected on erythrocytes, is essential for the correct assembly of human basement membranes in kidney and skin. Blood 2004;104:2217–2223.
65. Nikopoulos K, Gilissen C, Hoischen A, van Nouhuys CE, Boonstra FN, Blokland EA, Arts P, Wieskamp N, Strom TM, Ayuso C, et al. Next-generation sequencing of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with familial exudative vitreoretinopathy. Am J Hum Genet 2010;86:240–247.
66. Poulter JA, Ali M, Gilmour DF, Rice A, Kondo H, Hayashi K, Mackey DA, Kearns LS, Ruddle JB, Craig JE, et al. Mutations in TSPAN12 cause autosomal-dominant familial exudative vitreoretinopathy. Am J Hum Genet 2010;86:248–253.
67. van Zelm MC, Smet J, Adams B, Mascart F, Schandene L, Janssen F, Ferster A, Kuo CC, Levy S, van Dongen JJ, et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest 2010;120:1265–1274.
68. Goschnick MW, Lau LM, Wee JL, Liu YS, Hogarth PM, Robb LM, Hickey MJ, Wright MD, Jackson DE., Impaired “outside-in” integrin alphaIIbbeta3 signaling and thrombus stability in TSSC6-deficient mice. Blood 2006;108:1911–1918.
69. Orlowski E, Chand R, Yip J, Wong C, Goschnick MW, Wright MD, Ashman LK, Jackson DE., A platelet tetraspanin superfamily member, CD151, is required for regulation of thrombus growth and stability in vivo. J Thromb Haemost 2009;7:2074–2084.
70. Haining EJ, Yang J, Tomlinson MG., Tetraspanin microdomains:fine-tuning platelet function. Biochem Soc Trans 2011;39:518–523.
71. Protty MB, Watkins NA, Colombo D, Thomas SG, Heath VL, Herbert JM, Bicknell R, Senis YA, Ashman LK, Berditchevski F, et al. Identification of Tspan9 as a novel platelet tetraspanin and the collagen receptor GPVI as a component of tetraspanin microdomains. Biochem J 2009;417:391–400.
72. Tomlinson MG., Platelet tetraspanins:small but interesting. J Thromb Haemost 2009;7:2070–2073.
73. Uchtmann K, Park ER, Bergsma A, Segula J, Edick MJ, Miranti CK., Homozygous loss of mouse tetraspanin CD82 enhances integrin alphaIIbbeta3 expression and clot retraction in platelets. Exp Cell Res 2015;339:261–269.
74. Mangin PH, Kleitz L, Boucheix C, Gachet C, Lanza F., CD9 negatively regulates integrin alphaIIbbeta3 activation and could thus prevent excessive platelet recruitment at sites of vascular injury. J Thromb Haemost 2009;7:900–902.
75. Schroder J, Lullmann-Rauch R, Himmerkus N, Pleines I, Nieswandt B, Orinska Z, Koch-Nolte F, Schroder B, Bleich M, Saftig P., Deficiency of the tetraspanin CD63 associated with kidney pathology but normal lysosomal function. Mol Cell Biol 2009;29:1083–1094.
76. Arduise C, Abache T, Li L, Billard M, Chabanon A, Ludwig A, Mauduit P, Boucheix C, Rubinstein E, Le Naour F., Tetraspanins regulate ADAM10-mediated cleavage of TNF-alpha and epidermal growth factor. J Immunol 2008;181:7002–7013.
77. Dornier E, Coumailleau F, Ottavi JF, Moretti J, Boucheix C, Mauduit P, Schweisguth F, Rubinstein E., TspanC8 tetraspanins regulate ADAM10/Kuzbanian trafficking and promote Notch activation in flies and mammals. J Cell Biol 2012;199:481–496.
78. Haining EJ, Yang J, Bailey RL, Khan K, Collier R, Tsai S, Watson SP, Frampton J, Garcia P, Tomlinson MG., The TspanC8 subgroup of tetraspanins interacts with A disintegrin and metalloprotease 10 (ADAM10) and regulates its maturation and cell surface expression. J Biol Chem 2012;287:39753–39765.
79. Xu D, Sharma C, Hemler ME., Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. Faseb j 2009;23:3674–3681.
80. Prox J, Willenbrock M, Weber S, Lehmann T, Schmidt-Arras D, Schwanbeck R, Saftig P, Schwake M., Tetraspanin15 regulates cellular trafficking and activity of the ectodomain sheddase ADAM10. Cell Mol Life Sci 2012;69:2919–2932.
81. Wong E, Maretzky T, Peleg Y, Blobel CP, Sagi I., The functional maturation of A disintegrin and metalloproteinase (ADAM) 9, 10, and 17 requires processing at a newly identified proprotein convertase (PC) cleavage site. J Biol Chem 2015;290:12135–12146.
82. Jouannet S, Saint-Pol J, Fernandez L, Nguyen V, Charrin S, Boucheix C, Brou C, Milhiet PE, Rubinstein E., TspanC8 tetraspanins differentially regulate the cleavage of ADAM10 substrates, Notch activation and ADAM10 membrane compartmentalization. Cell Mol Life Sci 2016;73:1895–1915.
83. Zhou J, Fujiwara T, Ye S, Li X, Zhao H., Downregulation of Notch modulators, tetraspanin 5 and 10, inhibits osteoclastogenesis in vitro. Calcif Tissue Int 2014;95:209–217.
84. Noy PJ, Yang J, Reyat JS, Matthews AL, Charlton AE, Furmston J, Rogers DA, Rainger GE, Tomlinson MG., TspanC8 tetraspanins and A disintegrin and metalloprotease 10 (ADAM10) interact via their extracellular regions:Evidence for distinct binding mechanisms for different TspanC8s. J Biol Chem 2016;291:3145–3157.
85. Kuhn S, Koch M, Nubel T, Ladwein M, Antolovic D, Klingbeil P, Hildebrand D, Moldenhauer G, Langbein L, Franke WW, et al. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 2007;5:553–567.
86. Zeiler M, Moser M, Mann M., Copy number analysis of the murine platelet proteome spanning the complete abundance range. Mol Cell Proteomics 2014;13:3435–3445.
87. Burkhart JM, Vaudel M, Gambaryan S, Radau S, Walter U, Martens L, Geiger J, Sickmann A, Zahedi RP., The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012;120:e73–e82.
88. Bergbold N, Lemberg MK., Emerging role of rhomboid family proteins in mammalian biology and disease. Biochim Biophys Acta 2013;1828:2840–2848.
89. Freeman M., The rhomboid-like superfamily:molecular mechanisms and biological roles. Annu Rev Cell Dev Biol 2014;30:235–254.
90. Langosch D, Scharnagl C, Steiner H, Lemberg MK., Understanding intramembrane proteolysis:from protein dynamics to reaction kinetics. Trends Biochem Sci 2015;40:318–327.
91. Adrain C, Zettl M, Christova Y, Taylor N, Freeman M., Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science 2012;335:225–228.
92. McIlwain DR, Lang PA, Maretzky T, Hamada K, Ohishi K, Maney SK, Berger T, Murthy A, Duncan G, Xu HC, et al. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science 2012;335:229–232.
93. Siggs OM, Xiao N, Wang Y, Shi H, Tomisato W, Li X, Xia Y, Beutler B., iRhom2 is required for the secretion of mouse TNFalpha. Blood 2012;119:5769–5771.
94. Zettl M, Adrain C, Strisovsky K, Lastun V, Freeman M., Rhomboid family pseudoproteases use the ER quality control machinery to regulate intercellular signaling. Cell 2011;145:79–91.
95. Issuree PD, Maretzky T, McIlwain DR, Monette S, Qing X, Lang PA, Swendeman SL, Park-Min KH, Binder N, Kalliolias GD, et al. iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. J Clin Invest 2013;123:928–932.
96. Christova Y, Adrain C, Bambrough P, Ibrahim A, Freeman M., Mammalian iRhoms have distinct physiological functions including an essential role in TACE regulation. EMBO Rep 2013;14:884–890.
97. Li X, Maretzky T, Weskamp G, Monette S, Qing X, Issuree PD, Crawford HC, McIlwain DR, Mak TW, Salmon JE, et al. iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling. Proc Natl Acad Sci USA 2015;112:6080–6085.
98. Blaydon DC, Etheridge SL, Risk JM, Hennies HC, Gay LJ, Carroll R, Plagnol V, McRonald FE, Stevens HP, Spurr NK, et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet 2012;90:340–346.
99. Saarinen S, Vahteristo P, Lehtonen R, Aittomaki K, Launonen V, Kiviluoto T, Aaltonen LA., Analysis of a Finnish family confirms RHBDF2 mutations as the underlying factor in tylosis with esophageal cancer. Fam Cancer 2012;11:525–528.
100. Brooke MA, Etheridge SL, Kaplan N, Simpson C, O’Toole EA, Ishida-Yamamoto A, Marches O, Getsios S, Kelsell DP., iRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function. Hum Mol Genet 2014;23:4064–4076.
101. Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM, Brooke MA, van Heel DA, Ruschendorf F, Toynbee M, Walne A, et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med 2011;365:1502–1508.
102. Maney SK, McIlwain DR, Polz R, Pandyra AA, Sundaram B, Wolff D, Ohishi K, Maretzky T, Brooke MA, Evers A, et al. Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17. Sci Signal 2015;8:ra109.
103. Maretzky T, McIlwain DR, Issuree PD, Li X, Malapeira J, Amin S, Lang PA, Mak TW, Blobel CP., iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding. Proc Natl Acad Sci USA 2013;110:11433–11438.